KALY - Kali-Extracts Brand Name Gains Momentum In Cannabis Extraction Market
June 04 2019 - 03:25PM
InvestorsHub NewsWire
KALY - Kali-Extracts Brand Name
Gains Momentum In Cannabis Extraction Market
Dallas, TX -- June 4, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced an agreement with a New York
State Licensed Hemp Cultivation Operation anticipated to generate
an estimated $5 million in revenue for KALY. A key aspect of
why the New York State Licensed Hemp Cultivation Operation selected
Kali-Extracts is because of Kali-Extracts growing brand recognition
for high quality extracts. KALY owns and operates a U.S.
Patented Cannabis Extraction Process. The company is
advancing biotechnology research for the future production of
cannabis extract centric pharmaceuticals and at the same time, the
company is currently generating revenue from the sale of CBD
infused consumer products. The New York State Licensed Hemp
Cultivation Operation believes the consignment of its hemp crop to
KALY to extract and sell CBD extract under the Kali-Extracts brand
name will drive higher volume sales with higher profitability under
the Kali-Extracts brand name then if they went it alone. KALY
management believes this first consignment and extraction contract
is just the beginning and that the company can sign multiple
similar contracts which it can efficiently serve with its mobile
extraction lab.
KALY is
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from a proprietary cannabinoid
product platform in a broad range of disease areas. In the
fourth quarter of last year, 2018, KALY acquired NCM Biotech
(NCMB). In NCMB’s four years of operations, the company has
established a leading position in the development of plant-derived
cannabinoid therapeutics through a proven drug discovery and
patented development process. The resulting intellectual
property portfolio and the established regulatory and manufacturing
expertise have created a significant opportunity. KALY has a
deep pipeline of cannabinoid product candidates including four
distinct compounds. KALY has completed the first stage of
clinical development and testing for a Chronic Obstructive
Pulmonary Disease (COPD) therapy and is currently conducting phase
one development and trials for compounds targeting Cancer Pain
Management, Type 2 Diabetes and Epilepsy.
KALY is
not relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. With the popularity
of cannabis extracts for infusion into various consumer products,
KALY’s patented extraction process offers arguably the highest
quality extract to the infusion market. Drawing on KALY’s
patented cannabis extraction expertise, in addition to winning the
$5 million extraction contract announced today, KALY has partnered
with Puration (USOTC:
PURA) to lend its extraction expertise in the production of
EVERx CBD Sports Water, the leading CBD infused beverage for the
sports nutrition market. KALY has also introduced its own CBD
confections line, Hemp4mula with CBD infused gum already on the
market and gummies on the way. Hemp4mula is available on the
Ecommerce site USMJ.com hosted by North American Cannabis Holdings,
Inc. (USOTC:
USMJ) (aka USMJ). KALY’s non-pharmaceutical extraction
revenue strategy offers a business line that can stand alone, and
at the same time provide KALY with the long-term staying power to
bring its cannabis extract biopharmaceutical products to
market.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2023 to Mar 2024